These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 19877881)

  • 1. Radioiodinated metaiodobenzylguanidine treatment of neuroendocrine tumors in adults.
    Postema EJ; McEwan AJ
    Cancer Biother Radiopharm; 2009 Oct; 24(5):519-25. PubMed ID: 19877881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].
    Mukherjee JJ; Kaltsas GA; Islam N; Plowman PN; Foley R; Hikmat J; Britton KE; Jenkins PJ; Chew SL; Monson JP; Besser GM; Grossman AB
    Clin Endocrinol (Oxf); 2001 Jul; 55(1):47-60. PubMed ID: 11453952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects and safety of ¹³¹I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry.
    Yoshinaga K; Oriuchi N; Wakabayashi H; Tomiyama Y; Jinguji M; Higuchi T; Kayano D; Fukuoka M; Inaki A; Toratani A; Okamoto S; Shiga T; Ito YM; Nakajo M; Nakajo M; Kinuya S; ; ;
    Endocr J; 2014; 61(12):1171-80. PubMed ID: 25214026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ¹¹¹In-DTPA⁰-octreotide (Octreoscan), ¹³¹I-MIBG and other agents for radionuclide therapy of NETs.
    Bomanji JB; Papathanasiou ND
    Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1():S113-25. PubMed ID: 22388626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-specific-activity iodine 131 metaiodobenzylguanidine for the treatment of metastatic pheochromocytoma or paraganglioma: a novel therapy for an orphan disease.
    Jimenez C; Núñez R; Wendt R
    Curr Opin Endocrinol Diabetes Obes; 2020 Jun; 27(3):162-169. PubMed ID: 32250976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-body iodine-131 metaiodobenzylguanidine imaging for detection of bone metastases in patients with paraganglioma: comparison with bone scintigraphy.
    Inoue T; Yoshinaga K; Morita K; Shiga T; Kanegae K; Hirata K; Okamoto S; Tamaki N
    Ann Nucl Med; 2007 Jul; 21(5):307-10. PubMed ID: 17634850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 131I-MIBG therapy of neural crest tumours (review).
    Troncone L; Rufini V
    Anticancer Res; 1997; 17(3B):1823-31. PubMed ID: 9179240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms.
    Pasieka JL; McEwan AJ; Rorstad O
    Surgery; 2004 Dec; 136(6):1218-26. PubMed ID: 15657579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Outcomes of 125 Patients With Metastatic Pheochromocytoma or Paraganglioma Treated With 131-I MIBG.
    Thorpe MP; Kane A; Zhu J; Morse MA; Wong T; Borges-Neto S
    J Clin Endocrinol Metab; 2020 Mar; 105(3):e494-501. PubMed ID: 31614368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients.
    Safford SD; Coleman RE; Gockerman JP; Moore J; Feldman J; Onaitis MW; Tyler DS; Olson JA
    Cancer; 2004 Nov; 101(9):1987-93. PubMed ID: 15455358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan.
    Castellani MR; Chiti A; Seregni E; Bombardieri E
    Q J Nucl Med; 2000 Mar; 44(1):77-87. PubMed ID: 10932604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [(131)I] and [(125)I] metaiodobenzylguanidine therapy in macroscopic and microscopic tumors: a comparative study in SK-N-SH human neuroblastoma and PC12 rat pheochromocytoma xenografts.
    Rutgers M; Buitenhuis CK; van der Valk MA; Hoefnagel CA; Voûte PA; Smets LA
    Int J Cancer; 2000 Dec; 90(6):312-25. PubMed ID: 11180134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome and toxicity after dose-intensified treatment with 131I-MIBG for advanced metastatic carcinoid tumors.
    Ezziddin S; Sabet A; Logvinski T; Alkawaldeh K; Yong-Hing CJ; Ahmadzadehfar H; Grünwald F; Biersack HJ
    J Nucl Med; 2013 Dec; 54(12):2032-8. PubMed ID: 24101685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-Specific-Activity-
    Jha A; Taïeb D; Carrasquillo JA; Pryma DA; Patel M; Millo C; de Herder WW; Del Rivero J; Crona J; Shulkin BL; Virgolini I; Chen AP; Mittal BR; Basu S; Dillon JS; Hope TA; Mari Aparici C; Iagaru AH; Hicks RJ; Avram AM; Strosberg JR; Civelek AC; Lin FI; Pandit-Taskar N; Pacak K
    Clin Cancer Res; 2021 Jun; 27(11):2989-2995. PubMed ID: 33685867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical applications of dosimetry for mIBG therapy.
    Flux GD; Chittenden SJ; Saran F; Gaze MN
    Q J Nucl Med Mol Imaging; 2011 Apr; 55(2):116-25. PubMed ID: 21386786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 131I-metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors.
    Grünwald F; Ezziddin S
    Semin Nucl Med; 2010 Mar; 40(2):153-63. PubMed ID: 20113683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).
    Fitzgerald PA; Goldsby RE; Huberty JP; Price DC; Hawkins RA; Veatch JJ; Dela Cruz F; Jahan TM; Linker CA; Damon L; Matthay KK
    Ann N Y Acad Sci; 2006 Aug; 1073():465-90. PubMed ID: 17102115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 Study of High-Specific-Activity I-131 MIBG for Metastatic and/or Recurrent Pheochromocytoma or Paraganglioma.
    Noto RB; Pryma DA; Jensen J; Lin T; Stambler N; Strack T; Wong V; Goldsmith SJ
    J Clin Endocrinol Metab; 2018 Jan; 103(1):213-220. PubMed ID: 29099942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma.
    Safford SD; Coleman RE; Gockerman JP; Moore J; Feldman JM; Leight GS; Tyler DS; Olson JA
    Surgery; 2003 Dec; 134(6):956-62; discussion 962-3. PubMed ID: 14668728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-specific-activity
    Dillon JS; Bushnell D; Laux DE
    Future Oncol; 2021 Apr; 17(10):1131-1141. PubMed ID: 33506713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.